Smithfield Trust Co. reduced its stake in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) by 28.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,613 shares of the company’s stock after selling 2,631 shares during the quarter. Smithfield Trust Co.’s holdings in Reata Pharmaceuticals were worth $541,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in RETA. American Century Companies Inc. acquired a new position in Reata Pharmaceuticals in the 3rd quarter worth about $2,463,000. Engineers Gate Manager LP increased its holdings in Reata Pharmaceuticals by 66.8% in the 3rd quarter. Engineers Gate Manager LP now owns 40,114 shares of the company’s stock worth $3,280,000 after purchasing an additional 16,071 shares in the last quarter. Columbus Circle Investors acquired a new position in Reata Pharmaceuticals in the 3rd quarter worth about $3,035,000. First Trust Advisors LP acquired a new position in Reata Pharmaceuticals in the 3rd quarter worth about $263,000. Finally, Northern Trust Corp increased its holdings in Reata Pharmaceuticals by 41.5% in the 2nd quarter. Northern Trust Corp now owns 183,930 shares of the company’s stock worth $6,432,000 after purchasing an additional 53,946 shares in the last quarter. Hedge funds and other institutional investors own 40.73% of the company’s stock.
In other Reata Pharmaceuticals news, insider Keith Wayne Ward sold 4,750 shares of the company’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $59.48, for a total value of $282,530.00. Following the sale, the insider now owns 4,750 shares in the company, valued at approximately $282,530. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 23,750 shares of company stock worth $1,414,028 in the last quarter. Corporate insiders own 31.69% of the company’s stock.
NASDAQ RETA opened at $68.29 on Friday. Reata Pharmaceuticals Inc has a 12 month low of $19.31 and a 12 month high of $99.50. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -34.32 and a beta of 3.40.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.28). The business had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $9.50 million. On average, equities research analysts expect that Reata Pharmaceuticals Inc will post -2.56 earnings per share for the current fiscal year.
Reata Pharmaceuticals Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Featured Article: Bond
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.